Donor-Alloantigen-Reactive Regulatory T Cell (darTreg) Therapy in Renal Transplantation (The ONE Study )

Completed · Phase 1

Conditions studied: Kidney Disease

In brief

This Phase I pilot study will evaluate the safety, and tolerability of darTreg infusion for adult, de novo, living donor renal transplant recipients.

Key facts

Study ID

NCT02244801

Run by

University of California, San Francisco

People needed

6

Starts

2015-04-01

Expected to finish

2018-08-28

Last updated by the study team

2018-10-15

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

Where it is running

• University of California San Francisco - Transplant Department. 513 Parnassus Ave HSE 504 — San Francisco, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.